What is Adaptive Biotechnologies's investing cash flow?

Adaptive Biotechnologies (ADPT) reported investing cash flow of $9.14M in Q1 2026.

How has Adaptive Biotechnologies's investing cash flow changed year-over-year?

Adaptive Biotechnologies's investing cash flow decreased by 64.2% year-over-year, from $25.57M to $9.14M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Adaptive Biotechnologies ADPT Investing Cash Flow

Investing Cash Flow at other companies

Guardant HealthGH

$699.42M+131%

Natera, Inc.NTRA

-$32.14M-91.1%

Monte Rosa Therapeutics, Inc.GLUE

-$261M-160%

GeneDx HoldingsWGS

-$17.26M-83.4%

VeracyteVCYT

-$127.96M-147%

Nurix Therapeutics, Inc.NRIX

-$123.83M-585%

Other financials

Income statement

See full

Revenue$70.9M+35.1%

Gross profit$52.2M+47.1%

Operating income-$19.2M+35.1%

Net income-$20.0M+32.9%

EPS (diluted)-$0.13+35.0%

Balance sheet

See full

Cash & equivalents$77.6M+53.2%

Total debt$208.2M-5.6%

Total equity$216.3M+13.6%

Total assets$505.9M-1.0%

Cash flow

See full

Operating cash flow-$9.5M+66.5%

CapEx$796.0K-36.8%

Free cash flow-$10.3M+65.3%

Valuation

See full

Market cap$2.76B+93.6%

Enterprise value$2.89B+78.0%

P/S9.3×+1.8×

Profitability

See full

Gross margin75.3%+12.7pp

Operating margin-15.8%-7.0pp

Net margin-16.8%-7.3pp

FCF margin-10.5%-4.6pp

Returns & leverage

See full

Return on equity-24.4%-9.2pp

Debt / equity1×-0.2×

Current ratio3.4×+0.4×

Where this comes from

Reported directly by Adaptive Biotechnologies in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Adaptive Biotechnologies's investing cash flow?: Adaptive Biotechnologies (ADPT) reported investing cash flow of $9.14M in Q1 2026.
How has Adaptive Biotechnologies's investing cash flow changed year-over-year?: Adaptive Biotechnologies's investing cash flow decreased by 64.2% year-over-year, from $25.57M to $9.14M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.